Recent News

• 02.12.2026 - Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
• 02.09.2026 - Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
• 01.27.2026 - Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
• 01.27.2026 - Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
• 01.20.2026 - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 01.05.2026 - Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Recent Filings

• 02.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.02.2026 - 144 Report of proposed sale of securities